Remove 2018 Remove Pharmaceuticals Remove Pharmacokinetics
article thumbnail

Gepirone

New Drug Approvals

2] Gepirone was synthesized by Bristol-Myers Squibb in 1986 and was developed and marketed by Fabre-Kramer Pharmaceuticals. [4] Jump up to: a b c d e “Gepirone – Fabre-Kramer Pharmaceuticals” AdisInsight. Retrieved 23 January 2018. 1] It is taken orally. [1] American Psychiatric Pub. ISBN 978-1-58562-821-6.

FDA 62
article thumbnail

Orforglipron’

New Drug Approvals

1] It was discovered by Chugai Pharmaceutical Co. then was licensed to Lilly in 2018. [1] Orforglipron ( LY-3502970 ) is an oral, non-peptide, small-molecule GLP-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company. [1] percentage points from a starting level of 8%. [1] kg), on average after 40 weeks. [1]

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Landiolol

New Drug Approvals

0004]The synthesis of Landiolol 1 is disclosed in US 5013734 , JP 3302647 , CN 100506814 , JP 2539734 and Chemical & Pharmaceutical Bulletin 1992, 40 (6) 1462-1469. “Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting beta-blocker, in patients with cardiac arrhythmias” Clinical Pharmacology and Therapeutics.

FDA 62
article thumbnail

Best-in-Class Solutions Accelerate Development of GLP-1 Therapeutics

PPD

Medical researchers and practitioners see in their own patients how these ailments interconnect and overlap, as do the pharmaceutical and biotech companies working to develop GLP-1 therapeutics. It is worth noting that trial ran from 2018 to 2021, before the U.S.

article thumbnail

Hetrombopag Olamine

New Drug Approvals

49 Akilo-scale, chromatography-freesynthesisofhetrombopag has been reported by researchers at Jiangsu Hengrui Pharmaceutical in the Chinese-language patent literature (Scheme 12).50,51 2018, 22, 5367−5377. (48) Safety, pharmacokinetics and pharmacodynamics of hetrombopag olamine, a novel TPO-R agonist, in healthy individuals.

article thumbnail

Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA

The Pharma Data

Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics study Adalimumab’s high-concentration 100 mg/mL formulation aims to provide an enhanced yet familiar experience for patients Submission builds on Sandoz’ well established biosimilar immunology portfolio in Europe.

article thumbnail

ATICAPRANT

New Drug Approvals

4] [6] Aticaprant was originally developed by Eli Lilly , was under development by Cerecor for a time, and is now under development by Janssen Pharmaceuticals. [2] 14] Pharmacokinetics The oral bioavailability of aticaprant is 25%. [1] 14] Pharmacokinetics The oral bioavailability of aticaprant is 25%. [1] 30 January 2018.